

ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

3 April 2020

Dear Shareholders,

Election of Language and Means of Receipt of Corporate Communications

Pursuant to Rules 2.07A and 2.07B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association of CK Life Sciences Int'l. (Holdings) Inc. (the "Company"), the Company is making available to you certain options for receipt of future corporate communications of the Company ("Corporate Communications"), which means any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to: (a) the directors' reports, its annual accounts together with a copy of the auditor's reports and, where applicable, its summary financial reports; (b) the interim reports and, where applicable, its summary interim reports; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form. The options are:

- Option 1: to receive by mail the printed English version of all future Corporate Communications only; or
- Option 2: to receive by mail the printed Chinese version of all future Corporate Communications only; or
- Option 3: to receive by mail both the printed English and Chinese versions of all future Corporate Communications; or
- Option 4: to access all future Corporate Communications through the website of the Company at www.ck-lifesciences.com ("Website Version") instead of receiving printed copies by mail.

In support of the environment minimising the use of paper and saving printing and mailing costs, the Company recommends that you select Option 4 above to receive the Website Version of all Corporate Communications in future. To elect, please mark a "X" in the appropriate box on the enclosed reply form and return it signed to the Company c/o its Branch Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong. If you post the enclosed reply form in Hong Kong, you may use the freepost mailing label provided when returning the reply form. If you are mailing from overseas, please affix an appropriate stamp.

If the Company does not receive the reply form or a response from you by 4 May 2020, you will be deemed to have consented to receiving the Website Version of all future Corporate Communications, and a notification of the posting of Corporate Communications on the website of the Company will be sent to you in the future.

You are entitled to change the choice of language and/or means of receipt of future Corporate Communications at any time by reasonable prior notice in writing to the Company c/o its Branch Share Registrar or sending a notice to cklife.com@computershare.com.hk. Even if you have elected (or are deemed to have consented) to receive the Website Version of all future Corporate Communications, if for any reason you have difficulty in accessing the Corporate Communications posted on the Company's website, the Company will, upon receipt of a written request, promptly send you the Corporate Communications in printed form free of charge.

Please note that: (a) printed copies of the English and Chinese versions of all future Corporate Communications will be available from the Company or its Branch Share Registrar upon request; and (b) the Website Version of both English and Chinese versions of all future Corporate Communications will also be available on the Company's website at www.ck-lifesciences.com and the website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk.

Should you have any queries in relation to this letter, please call the Company's telephone hotline at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays) from 3 April 2020 to 4 May 2020.

Yours faithfully,

CK Life Sciences Int'l. (Holdings) Inc.

CKLH-03042020-1(7)